Introduction {#s0005}
============

In the year 1988, two neuro-muscular disorders were associated with the first pathogenic defects of mitochondrial DNA (mtDNA), starting the molecular era of mitochondrial medicine ([@bb0540; @bb1190]). Leber\'s hereditary optic neuropathy (LHON), one of the two, is a form of optic nerve degeneration inherited through the maternal line associated with a point mutation affecting the *MT*-*ND4* subunit gene of the respiratory complex I ([@bb1190]). Since then, optic nerve atrophy has been recognized as a frequent hallmark of mitochondrial diseases and many neurodegenerative diseases have been discovered to have a primary molecular defect involving mitochondrial proteins ([@bb0065; @bb0295; @bb1325]). Furthermore, mitochondrial dysfunction has been documented as a key pathogenic mechanism in many neurodegenerative disorders, even in those without a primary mitochondrial etiology ([@bb1020; @bb1175; @bb0775]). Finally, the introduction of new tools, such as optical coherence tomography (OCT) in ophthalmology, accurately assessed the optic nerve pathology in neurodegenerative diseases, such as Parkinson\'s disease, revealing patterns suggestive of mitochondrial neurodegeneration ([@bb0650]). Thus, the eye is a "mito-window" on the brain and this review will consider the retinal ganglion cells (RGCs) and related axons composing the optic nerve as a model system for mitochondrial neurodegeneration.

Optic neuropathy in mitochondrial diseases: clinical features {#s0010}
=============================================================

Non-syndromic: Leber\'s hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA) {#s0015}
-------------------------------------------------------------------------------------------

LHON and DOA are both characterized by an extreme selectivity of their tissue expression, which is limited to the RGCs and their axons in the optic nerve, with a preferential involvement of the small fibers in the papillomacular bundle that subserve central vision ([@bb0245; @bb1275]).

LHON patients, mostly young-adult males, typically undergo rapid and painless loss of central vision, which is bilateral in most cases, or involves sequentially one eye first and subsequently the other. The visual loss usually begins with defective color vision and central scotoma on the visual field. Loss of visual acuity stabilizes within the first year after onset, leaving the patient, in most cases, legally blind. Fundus changes characteristic of the subacute stage include peripapillary telangiectatic microangiopathy, swelling of the nerve fiber layer around the optic disk (pseudoedema) and lack of leakage on fluorescein angiography (in contrast to true edema). The optic disk appears hyperemic and eventually axonal loss in the papillomacular bundle leads to temporal pallor of the disk. In time, the optic disk turns completely pale.

The endpoint of LHON is usually optic atrophy with permanent loss of central vision and relative sparing of the pupillary light responses. Spontaneous recovery of visual acuity has been reported occasionally, with contraction of the scotoma or reappearance of small islands of vision within it (fenestration). The most favorable prognostic factors are young age of onset and type of pathogenic mutation, the 14484/*MT-ND6* mutation being most commonly associated with spontaneous recovery ([@bb0270]). The chronic stage of LHON may be characterized by a further slowly progressing deterioration of visual functions, difficult to be objectively measured, but subjectively reported by patients and documented in a few cases studied post-mortem as evidence of still ongoing neurodegeneration ([@bb0235; @bb0245]).

The recent use of OCT to measure retinal nerve fiber layer (RNFL) thickness provided anatomical quantitative features describing the subacute and chronic stages of LHON, as well as the unaffected mutation carriers and the recovery of vision. The crucial timing of LHON subacute conversion, detailed by OCT serial studies, demonstrated a precise pattern of axonal swelling followed by reduction, starting from the infero-temporal sector (papillo-macular bundle), followed by the superior and only lastly by the nasal quadrants, the latter usually the most spared by degeneration ([@bb0095]). This pattern matched that observed by the few postmortem studies of optic nerve specimens ([@bb0950; @bb0235; @bb0245; @bb0265]). In chronic LHON OCT showed a consistent decrease of RNFL thickness in all quadrants, which was significantly less severe in those patients recovering vision ([@bb0080]). In unaffected mutation carriers the OCT showed a consistent increase of RNFL thickness (swelling) in the temporal/inferior quadrant, indicating a subclinical diseases of papillomacular bundle ([@bb0980]). Finally, the conformation of the optic nerve head has been substantiated by OCT as an "anatomical" risk factor for LHON, the small "at risk" disk being associated with conversion to affected status and a more severe final outcome ([@bb0885]).

DOA patients, differently from LHON, present with slowly progressive, bilateral loss of central vision in childhood, accompanied by centrocaecal scotomas, impairment of color vision, temporal pallor of the optic disks and relative preservation of the pupillary reflex. The disease affects both sexes and is frequently so mild as to be recognized only during routine vision testing (school or driving license eye screenings). Its progression may vary within the same family, ranging from mild cases with visual acuity that stabilizes in adolescence, to slowly but relentlessly progressing cases, to severe cases with congenital optic atrophy. A distinct subgroup of LHON cases with childhood onset, especially if presenting with a slowly progressive clinical course, may pose serious problems of differential diagnosis with DOA ([@bb0085]).

Despite the remarkably different clinical course, the endpoint of the pathological process in DOA is clinically indistinguishable from that in LHON, with a possible end-stage optic disk excavation, which may also be reported in LHON. The spontaneous recovery of visual acuity in DOA patients has not been reported, with a rare exception ([@bb0245; @bb1275; @bb0340; @bb0350]).

OCT studies in DOA defined quantitatively the optic atrophy, showing a decreased RNFL thickness, with a smaller average optic disk size, which suggests a reduced complement of axons at birth, compatible with severe congenital disease as a frust form of optic nerve hypoplasia ([@bb0090; @bb0100]). The very few post-mortem studies of DOA showed selective loss of RGCs, particularly in the macular area, optic nerve axonal loss and demyelination, especially in the temporal aspect suggesting vulnerability of the papillomacular fibers as in LHON ([@bb0625]).

An interesting feature shared by LHON and DOA is the occurrence, in a subset of cases, of white matter lesions, which may be indistinguishable from multiple sclerosis (MS) in terms of clinical and laboratory expression ([@bb0525; @bb1165]). This association of MS-like features with mitochondrial optic neuropathies seems to be causally related and not merely a coincidental occurrence of two overlapping diseases ([@bb0260]).

Syndromic: the overlapping LHON/MELAS/Leigh syndrome and DOA plus (OPAopathies) {#s0020}
-------------------------------------------------------------------------------

LHON-like optic neuropathy has been described frequently in association with spastic dystonia and bilateral lesions in the basal ganglia, mainly bilateral striatal necrosis ([@bb0190; @bb0810]). Optic atrophy is also a frequent, but mostly overlooked feature of Leigh syndrome, a severe pediatric condition characterized by bilateral lesions of the central nervous system, usually extending from the basal ganglia to the brainstem ([@bb0300]). Furthermore, LHON-like optic neuropathy is increasingly recognized in association with stroke-like episodes, typical for the MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes) ([@bb1185; @bb0875]). We recently reviewed this topic ([@bb0265]) and emphasized that in many families the same mtDNA mutation, invariably affecting one of the ND subunits of complex I, may lead to each of the above mentioned clinical features alone or in combination in a bridging phenotype of LHON/MELAS/Leigh syndrome with the possible common pathogenic feature of mitochondrial vasculopathy ([@bb0875; @bb0330; @bb0140; @bb1080]). Prominent optic atrophy in the contest of mitochondrial encephalomyopathy has also been associated with cytochrome c oxidase subunit I (COX I) mutation or with mtDNA deletion ([@bb0185; @bb0915]).

In 2008, we and others described the occurrence of a multisystemic disorder characterized by severe optic atrophy and sensorineural deafness, associated with cerebellar ataxia, axonal sensory--motor polyneuropathy, and late chronic progressive external ophthalmoplegia (CPEO) and ptosis due to a subgroup of missense mutations in the optic atrophy 1 (*OPA1*) gene, which was defined as DOA "plus" syndrome ([@bb0020; @bb0550]). The most important observation in these patients was that they all had a mitochondrial myopathy with accumulation of multiple mtDNA deletions, thus implicating the *OPA1* gene function in mtDNA maintenance. Interestingly, a single report recently presented a similar phenotype associated with compound heterozygote mutations in the polymerase gamma (*POLG1*) gene, demonstrating a genetic heterogeneity of optic atrophy associated with mitochondrial myopathy and mtDNA multiple deletions ([@bb0765]). Over recent years, other phenotypes have been described within the frame of the OPA1-related DOA "plus" syndrome with mtDNA multiple deletions, including MS-like features, Behr-like spastic paraparesis and cases with absent or subclinical ocular involvement, thus defining an increasingly large spectrum of "*OPAopathies*" ([@bb1270; @bb0760; @bb0730; @bb0870; @bb1010]).

Remarkably, also mutations in mitofusin 2 (MFN2), another protein involved in mitochondrial fusion as OPA1 (see following sections), have been found in Charcot--Marie--Tooth axonal neuropathy type 2A (CMT2A) with optic atrophy, fulfilling the diagnostic criteria for Hereditary Motor Sensory Neuropathy type VI (HMSNVI) ([@bb1325; @bb1330]). These HMSNVI/CMT2A patients mostly presented with subacute visual loss, central scotoma, color vision defects and optic atrophy. They may experience, over years, variable degrees of recovery of visual acuity, sometimes reverting back to near normal visual function ([@bb1330]). Of note, a single family was recently reported with a MFN2 mutation segregating with optic atrophy beginning in early childhood, associated with axonal neuropathy and mitochondrial myopathy with mtDNA multiple deletions in adult life, closely resembling the DOA "plus" phenotype usually associated with OPA1 mutations, thus demonstrating genetic heterogeneity ([@bb0925]).

Intriguingly, optic atrophy may also complicate the clinical picture of families with autosomal recessive spastic paraplegia due to mutations in the spastic paraplegia 7 (*SPG7*) gene encoding for paraplegin, a mitochondrial metalloprotease of the AAA family, but unfortunately, description of the ophthalmological features in these patients is wanting ([@bb0295]).

Optic neuropathy is also a common feature in other multi-systemic mitochondrial disorders due to nuclear gene mutations, such as Friedreich ataxia (recessive-FRDA) ([@bb0215; @bb0065]), the Behr-like Costeff syndrome (recessive-*OPA3*) ([@bb0045]), recessive optic atrophy (*OPA7*/ROA1) with deafness ([@bb0520]; Meyer et al., 2010), X-linked deafness--dystonia--optic atrophy syndrome (Mohr--Tranebjaerg syndrome) ([@bb0585; @bb0640]) and a recessive syndrome of late-onset optic atrophy and ataxia with mutations in complex II ([@bb1115; @bb0135]). This latter entity, observed in a single family to date, has an interesting overlap with FRDA, sharing both disorders complex II deficiency, which in FRDA is extended to all enzymes with sulfur--iron clusters. They also share a similar pattern of visual loss, starting from the periphery of the visual field, which is not canonical for mitochondrial disorders ([@bb0425]). Further, two interesting reports mention the occurrence of optic atrophy in very severe infantile encephalopathies due to novel mutations in two important mitochondrial proteins, the mitochondrial fission dynamin-1-like protein (DNML1) and the apoptosis induction factor (AIF) ([@bb1210; @bb0460]).

Last, we mention the recessive Wolfram syndrome, characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness (DIDMOAD), which has been controversially included as a mitochondrial disorder ([@bb1180; @bb0205; @bb0110]). Causative mutations for Wolfram syndrome have been reported in two different genes, *WFS1* and *CISD2* ([@bb0555; @bb0030]), encoding proteins localized respectively on endoplasmic reticulum (ER) and on mitochondrial outer membrane (OM) and ER ([@bb9010]). Given the prevalent mitochondrial localization of CISD2 and the possible role played by both WFS1 and CISD2 in calcium homeostasis, the debate on mitochondrial involvement in the pathogenic mechanism of Wolfram syndrome remains open ([@bb0600]).

Optic neuropathy genetics {#s0025}
=========================

Mitochondrial inheritance {#s0030}
-------------------------

The maternal inheritance of LHON, clearly recognized a few decades ago, led to the identification of the frequent point mutations at positions 11778/*MT-ND4*, 3460/*MT-ND1*, and 14484/*MT-ND6*, which are found in over 90% of LHON cases worldwide ([@bb0245; @bb1275]). LHON can be also due to rare pathogenic mtDNA point mutations affecting different subunits of complex I, more commonly the *MT-ND6* and *MT-ND1* subunit genes ([@bb0325; @bb1140]) (see [Table 1](#t0005){ref-type="table"}). The mtDNA pathogenic mutations, which are in most cases homoplasmic (100% of the mtDNA molecules are mutated), do not explain at least two features of LHON: the male prevalence and the incomplete penetrance. Thus, the mtDNA mutation is a necessary but not a sufficient condition for the pathology, and additional genetic determinants, such as nuclear modifying genes, have been postulated ([@bb0240]). The X chromosome has been considered for a long time as a good candidate to explain both gender difference and variable penetrance by hypothesizing a two-loci model (mitochondrial pathogenic plus nuclear modifying) ([@bb0195]). However, despite the identification of some loci, no modifying genes on the X-chromosome have been truly established to date ([@bb0545; @bb1030; @bb0580]).

The only strong evidence of a genetic modifier is currently the association of LHON with a European mtDNA background, known as haplogroup J, which increases the penetrance of the 11778/*MT-ND4* and 14484/*MT-ND6* LHON mutations ([@bb0250; @bb0550]). The modifying effect of haplogroup J is thought to be due to specific arrays of complex I and III non-synonymous polymorphisms characterizing sub-haplogroup J1 for the 14484/ND6 mutation and sublineages J1c and J2b for the 11778/*MT-ND4* mutation ([@bb0250]). A recent study, investigating OXPHOS efficiency in cybrid cells carrying different mtDNA haplogroups from normal people, revealed subtile defects in the OXPHOS capacity of cells carrying the haplogroup J mtDNA, which leads support to the modifying effect of this mitochondrial background on LHON penetrance ([@bb0475]).

In addition to the primary LHON mutations, many other point mutations affecting ND subunits of complex I have been reported in association with overlapping phenotypes, such as the LHON/MELAS/Leigh syndrome. These mutations affect most frequently the *MT-ND5*, *MT-ND6* and *MT-ND1* subunit genes, but also *MT-ND4*, *MT-ND3* and *MT-ND2* (see [Table 2](#t0010){ref-type="table"}). Some cases of syndromic and non-syndromic optic atrophy are associated with mtDNA mutations other than the ND subunits genes of complex I, such as, for example, in cytochrome b, COX I and ATPase 6 genes (see [Table 1](#t0005){ref-type="table"}).

Mendelian inheritance {#s0035}
---------------------

A growing list of optic atrophy loci (OPA) associated with Mendelian transmission of the trait (recessive, dominant and X-linked) has been building in recent years, with only a few mutant genes already identified (see [Table 3](#t0015){ref-type="table"}). In addition to those with a certified or highly probable mitochondrial etiology, optic atrophy is a frequent feature in many neurodegenerative monogenic inherited disorders, for which the link to mitochondria remains elusive (see [Table 4](#t0020){ref-type="table"}). However, the pattern of preferential involvement of the papillomacular bundle, a hallmark of mitochondrial etiology, may anticipate that many of these disorders will turn out to have a primary or secondary involvement of mitochondrial function ([@bb1240; @bb1090]).

Optic neuropathy in neurodegenerative diseases {#s0040}
==============================================

The retinal and optic nerve involvement in major neurodegenerative disorders, such as Parkinson and Alzheimer disease, has been described decades ago ([@bb0160; @bb0535]). However, recent technical improvements in eye investigation, such as OCT, gave great impetus to re-investigation of retinal and optic nerve involvement in neurodegenerative diseases, the eye being the most accessible part of the central nervous system.

Parkinson disease (PD) {#s0045}
----------------------

There have been several lines of evidence supporting the involvement of the retina and the optic nerve, as non-motor component, in the neurodegenerative process of PD ([@bb0170; @bb0050]). In particular, impaired visual acuity ([@bb1335]), abnormal contrast sensitivity ([@bb0165]), color vision abnormalities ([@bb1045]) and optic nerve degeneration have been described in PD ([@bb0050]).

Since 2004, OCT measurements in PD patients documented a reduction of the RNFL thickness in both early and more advanced stages of the disease. Some authors reported a preferential loss of fibers in the infero-temporal quadrants, consistent with the involvement of the papillo-macular bundle ([@bb0560; @bb1255; @bb0785]). Macular and foveal abnormalities have also been documented ([@bb0510]).

Our own study of 43 PD patients documented a subclinical optic neuropathy, affecting significantly only the nerve fibers entering the temporal quadrant of the optic disk ([@bb0650]). The contralateral eye was more affected than the ipsilateral to the most affected body side, supporting an asymmetry of the neurodegenerative process that involves both the substantia nigra and the eye on the same side. These results identified in PD patients a pattern of axonal loss typically seen in LHON and DOA, where the papillo-macular bundle is characteristically susceptible ([@bb0245]). Both diseases are associated with a complex I defect ([@bb0220; @bb0230; @bb1285; @bb1150; @bb0255; @bb0265]), which is also recognized as a key feature in the pathogenesis of PD, both in the sporadic cases as well as in the genetic forms ([@bb1015]), linking the current results with the pattern observed in LHON and DOA.

Alzheimer disease (AD) {#s0050}
----------------------

Complex visual complaints, including difficulties in reading or finding objects, depth perception, perceiving structure from motion, color recognition and contrast sensitivity abnormalities are frequent in AD ([@bb0495; @bb0940]). In 1986 it was shown by Hinton and colleagues, in post-mortem retina and optic nerves of AD patients, that there was loss of RGCs and related axons, involving preferentially the M-cell system, in the apparent absence of neurofibrillary or amyloid angiopathy ([@bb0535; @bb0945]). After this first report, other authors showed the presence of optic nerve degeneration, being more evident in the superior and inferior quadrants and in the foveal region in post-mortem tissues of AD patients ([@bb0145; @bb0150]).

More recently, the use of OCT allowed not only the objective measurements of RNFL, but also of macular thickness for in-vivo quantitative evaluation of RGCs loss in AD. Studies with this approach reported a reduction in the average measurements ([@bb0855; @bb0565; @bb9015; @bb0705; @bb0615]), as well as in the superior quadrant ([@bb0855; @bb0565; @bb0130; @bb0705; @bb0615]) and in the nasal quadrant ([@bb0855; @bb0565]). Remarkably, these studies revealed the lack of involvement of the temporal quadrant. Overall, the subclinical optic neuropathy in AD seems to affect the magnocellular component of RGCs, as documented both histologically ([@bb0535; @bb0945]) and more recently electro-physiologically ([@bb0970]). In this regard, it is of note that this pattern resembles that of glaucomatous optic neuropathy and, in fact, there is a documented evidence of increased prevalence of glaucoma in AD patients ([@bb0115]).

Mitochondrial function and dysfunction in optic nerve neurodegeneration {#s0055}
=======================================================================

The pathways leading to neurodegeneration of the RGCs and related optic nerve have been delineated over the last 20 years and include biochemical impairment of complex I, the consequent increase in reactive oxygen species (ROS) and activation of apoptosis. More recently, attention has been drawn to the role played by the mitochondrial network dynamics and mitophagy, as well as to the regulation of mitochondrial biogenesis as a compensatory strategy to mitochondrial dysfunction ([Fig. 1](#f0005){ref-type="fig"}).

Complex I {#s0060}
---------

Mitochondria are the primary source of ATP providing the energy required for cell functioning through oxidative phosphorylation (OXPHOS). All the five large enzymatic complexes constituting the OXPHOS system are situated in the inner mitochondrial membrane (IM), where, together with two mobile electron carriers, ubiquinone (CoQ) and cytochrome c (cyt *c*), they couple electron transport to the generation of an electrochemical proton gradient across the IM. This gradient can drive the synthesis of ATP from ADP and inorganic phosphate at the level of Complex V (F0/F1-ATP-synthase), and, in addition, is used for various energy-dependent processes, such as nuclear protein import, Ca2 + uptake, and ion translocation ([@bb0645]).

With approximately 45 subunits, Complex I (CI, NADH:ubiquinone oxidoreductase) is the largest of the respiratory multi-protein complexes; the subunits are encoded both by nuclear (38 subunits) and mitochondrial (7 subunits) genomes ([@bb0280]), 14 subunits constituting the highly conserved catalytic core ([@bb0180]). CI transfers two electrons from NADH to CoQ, generating ubiquinol (CoQH2) and producing the translocation of four protons from matrix to the inner membrane space (IMS) ([@bb0435]). During this step, electrons may prematurely escape from the electron transport chain and react with oxygen to form superoxide (O~2~^•−^), making the CI a major site of production of this oxygen radical ([@bb0400]).

[@bb0120] observed different expression levels of CI, evaluated by quantification of the nuclear subunit NDUFA9 (NADH dehydrogenase ubiquinone 1 alpha subunit 9), in rat heart, muscle, brain, liver and kidney. They also found a strong correlation between CI expression and OXPHOS activity in these tissues: heart and muscle had the highest CI expression and OXPHOS activity, liver and kidney the lowest, and brain presented as intermediate CI expression and OXPHOS capacity ([@bb0120]). As a consequence, different tissues may show a different sensitivity to OXPHOS defects.

Dysfunction of CI is the most frequent defect of mitochondrial energetic metabolism ([@bb1055; @bb0395]) and represents a common feature of mitochondrial optic neuropathies. LHON is due to three common mutations affecting mitochondrial CI subunits, which induce moderate to severe impairment of CI activity, depending on the mutation ([@bb0245]). Studies with different CI inhibitors also indicated that all three mutations affect the interaction between CI and ubiquinone ([@bb0245]) and consistently decrease ATP synthesis driven by complex I substrates, confirming that CI is defective in LHON ([@bb0075]). Similarly, reduced ATP synthesis driven by CI substrates was found in patient-derived fibroblasts carrying different OPA1 mutations ([@bb1285; @bb0315]). Co-immunoprecipitation experiments showed that OPA1 directly interacts with CI subunits, possibly regulating its assembly and stabilization ([@bb1285]). The existence of a common biochemical OXPHOS defect, shared by LHON and DOA, was further corroborated by *in vivo* ^31^P-MRS studies of skeletal muscle ([@bb0690; @bb0695]).

The central theme of CI dysfunction in optic neuropathies also applies to the syndromic cases. For example, Leigh syndrome and the clinical overlapping phenotype of LHON/Dystonia/MELAS/Leigh syndrome have been associated with mutations in ND subunit genes, mainly *MT-ND5*, *MT-ND6* and *MT-ND1* ([@bb0265] and [Table 2](#t0010){ref-type="table"}). In FRDA the reduced amounts of frataxin may lead to impaired CI, confirming its central role in the mitochondrial Fe--S cluster biosynthesis ([@bb1085]). Also in MTS, Mohr Tranebjaerg syndrome, an altered import of nuclear-encoded subunits of CI, may lead to the loss of RGCs and depletion of axons in the optic nerve described in this syndrome ([@bb1135]). Finally, defective paraplegin was demonstrated to induce reduction of CI activity and increased sensitivity to oxidative stress ([@bb0295]), as well as a CI dysfunction may be part of the pathogenesis in PD, explaining the mitochondrial pattern of axonal loss in the optic nerve ([@bb0650]).

However, CI deficiency is not the only exclusive biochemical OXPHOS defect that leads to mitochondrial optic neuropathy. Other mtDNA mutations in structural genes such as cytochrome b, COX I, ATPase 6 ([Table 1](#t0005){ref-type="table"}) or mutations in tRNA genes have been associated with syndromic and non-syndromic optic atrophy ([@bb0320]). Furthermore, complex II deficiency, associated with a genetic defect in the nuclear-encoded flavoprotein subunit of complex II, may be associated with optic atrophy ([@bb1115; @bb0135]). Of note, besides CI, biochemical investigations of OPA1 mutant cells from DOA patients also showed a defective COX activity ([@bb0315]; *Valerio Carelli and Anna Ghelli*, *unpublished data*).

Reactive oxygen species {#s0065}
-----------------------

It is well known that mitochondria produce reactive oxygen species (ROS) as a consequence of electron leak during their transport. Superoxide radicals represent the primary ROS produced and complex I and complex III are the major superoxide (O~2~^•−^)-producing sites in mitochondria ([@bb0660]). The O~2~^•−^ is rapidly converted into hydrogen peroxide (H~2~O~2~) by manganese superoxide dismutase (MnSOD) and is further metabolized by glutathione peroxidase (GPX) to H~2~O. In the presence of transition metals, the H~2~O~2~ can also form the hydroxyl radical (OH^•^) through the Fenton reaction. Moreover, O~2~^•−^ may react with nitric oxide (NO•) leading to peroxynitrite (ONOO^•^) production.

ROS play a crucial role in regulating several cellular processes. ROS, when produced at low physiological concentration, are important messengers in cell signaling ([@bb0665]). However, if ROS levels overcome a threshold they can disrupt normal cellular function damaging DNA, proteins and lipids ([@bb0515]). Oxidative damage to mtDNA may cause an increased rate of mitochondrial genomic instability and accumulation of somatic mutations, ultimately leading to respiratory dysfunction and possibly contributing to cancer, premature aging and neurodegenerative diseases ([@bb0175]). Excessive ROS production may also cause local damage to the Fe--S clusters of respiratory enzymes (complexes I, II and III), as well as to tricarboxylic acid cycle enzymes (aconitase). Peroxynitrite can nitrate tyrosine residues or thiolic groups of nearby proteins and both CI and MnSOD have been reported to be damaged by this process ([@bb0920; @bb0755]). Another important damaging process is lipid peroxidation, which may affect several mitochondrial functions including OXPHOS, inner membrane barrier properties, maintenance of mitochondrial membrane potential (Δψm), and mitochondrial Ca2 + buffering capacity ([@bb1310; @bb0010; @bb0895]). In particular, an important target of ROS is cardiolipin (CL), an IM phospholipid involved in mitochondrial-dependent apoptosis and mitochondrial stability and dynamics ([@bb0865; @bb0070; @bb0850]), and its peroxidation plays a critical role in several patho-physiological mechanisms ([@bb0850]). ROS may also act as signaling molecules regulating function or expression of many proteins, including transcription factors (p53, JAK, NF-kb, HIF-1, etc.), kinases (p38, PKA, PKC, ERK, JNK, etc.), phosphatases (i.e. PTEN), ion channels and other mitochondrial proteins involved in apoptosis, dynamics, mitochondrial biogenesis, etc. ([@bb0645]). Thus, the balance between ROS production and their removal by antioxidant enzymes (superoxide dismutases, glutathione peroxidases and peroxiredoxins) is critical ([@bb0515]).

Increase of ROS production, as a consequence of CI dysfunction, has been observed in osteosarcoma (143B TK-)-derived ([@bb0125]) and in neuronal (NT2)-derived ([@bb1245]) cybrids carrying LHON mutations. Increased oxidative stress in DOA has recently been shown in a *Drosophila* model carrying a mutation in the *Opa1* gene and a multi-system phenotype ([@bb1250; @bb1105]). Oxidative stress could be decreased by treating these flies with vitamin E or superoxide dismutase 1 (SOD1), as well as by over-expressing human SOD1, partially reversing the pathological phenotype, and providing a strong indication of the possible role played by ROS in DOA ([@bb1250; @bb1105]). This issue has not been properly addressed in mammals yet, but appropriate experimental investigations of DOA in rodents model and human patients are warranted. Oxidative stress plays an important role also in FRDA, where the excess of free iron, due to defective frataxin, leads to an increased production of H~2~O~2~ ([@bb0055]). The ROS damaging role in FRDA has been also confirmed in a *Drosophila* model, in which H~2~O~2~ scavengers provided protective effects on the phenotype, contrary to O~2~^•−^ scavengers ([@bb0035]).

Overall, increased oxidative stress is a common feature in the pathophysiology of mitochondrial optic neuropathies.

Mitochondrial dynamics {#s0070}
----------------------

Mitochondria are highly dynamic organelles able to fuse and divide, depending on the energy requirement of the cell or in response to endogenous and exogenous stimuli. The morphology of the mitochondrial network results from a balance between the two antagonistic mechanisms of fusion, allowing an extended and interconnected reticular network, and fission that generates many mitochondria as distinct organelles ([@bb1220]). While the large network resulting from fusion metabolically supports the cells and regulates the response to calcium signals ([@bb1050; @bb1100]), fission is essential for proliferation and distribution of organelles in daughter cells after mitosis and is required for the elimination of old or damaged mitochondria through the autophagic process known as mitophagy ([@bb0845]). Furthermore, fission is also required for axoplasmic transport of mitochondria in neurons ([@bb0985]).

Many proteins regulating mitochondrial fusion and fission have been identified in the last 15 years, but the scenario is continuously evolving. Mitochondrial fusion is made possible by the coordinated action of pro-fusion OM (mitofusins, MFN1 and MFN2) and IM (OPA1) proteins, and additional scaffolding (Prohibitin 2, stomatin like protein-2) proteins in the IM. MFN1, MFN2 and OPA1 are all transmembrane proteins with a GTPase activity ([@bb0910; @bb0965; @bb0975]) and both MFN2 and OPA1 show additional non-fusion functions. In fact, MFN2 is involved in mitochondrial biogenesis ([@bb0290; @bb1320]) and in tethering mitochondria to the endoplasmic reticulum ([@bb0375]), whereas OPA1 participates to the *cristae* structure maintenance ([@bb0825; @bb0485]) and remodeling to prevent apoptosis ([@bb0430; @bb0335]) and ultimately is involved in mtDNA maintenance ([@bb0410]).

OPA1 exists in 8 different isoforms, generated by the alternative splicing of exon 4, exon 5 and exon 5b, that can be present or absent ([@bb0830]). The pattern of expression of these transcripts has been demonstrated to be tissue-specific in humans, with isoform 1 (containing only exon 4), isoform 3 (containing only exon 4b) and isoform 5 (containing exons 4 and 4b) being predominantly expressed in brain ([@bb0830]). Thus, the understanding of the physiological function of each OPA1 isoform and the characterization of the expression levels of each variant in human RGCs might help to clarify the pathogenetic mechanism responsible for OPA1-associated DOA and to work out innovative therapeutic strategies, such as replacement gene therapy.

Furthermore, OPA1 isoforms undergo proteolytic cleavage producing long isoforms (l-OPA1), anchored to the IM, and soluble short isoforms (s-OPA1), ([@bb0975; @bb0570; @bb0820]). Several proteases regulating mammalian OPA1 processing have been identified (PARL, m-AAA protease, OMA1, Yme1) and the balance of OPA1 processed isoforms has been demonstrated to affect the mitochondrial morphology, acting as an important regulatory mechanism of mitochondrial fusion ([@bb0335; @bb0490; @bb0570; @bb1070; @bb0405; @bb0530]).

In addition to proteases involved in the maintenance of OPA1 isoforms\' balance, other proteins that regulate mitochondrial fusion have been identified. Most of these proteins are regulators of other processes, such as apoptosis (Bax, Bak), mitophagy (Parkin), and remodeling of mitochondrial membrane lipids (MitoPLD, Lipin 1b), whereas mitofusin binding protein (MIB) negatively regulates MFN1 but is not involved in other mitochondrial processes ([@bb0845]).

Different proteins have been proposed to contribute to mitochondrial fission regulation, but so far only DNM1L has been demonstrated to play a direct role in fission ([@bb0790; @bb1060; @bb1065]). DNM1L is a cytosolic protein with GTPase activity, recruited on mitochondrial OM when fission occurs. DNM1L promotes OM fission through the assembly of multimeric ring complexes, coupling GTP hydrolysis with mitochondrial membrane constriction and fission ([@bb1295; @bb1065]). Some proteins have been proposed to mediate the recruitment of DNM1L on the OM, including mitochondrial fission protein 1 (FIS1) ([@bb1305]), mitochondrial fission factor (MFF) ([@bb0840; @bb0445]) and MiD proteins ([@bb0845]), although recently the interaction with FIS1 and its role in mitochondrial fission in mammals have been debated ([@bb0845]). Little is known about IM division, however MTP18 (mitochondrial fission protein 1), a phosphatidylinositol 3-kinase-dependent protein in IM membrane, has been proposed to play a role in this process ([@bb1125; @bb1130]).

What is known about the regulation of mitochondrial fission is so far limited to DNM1L post-translational modification, such as phosphorylation, S-nitrosylation, ubiquitanation and sumoylation ([@bb0845]).

The distribution of mitochondria in neuronal cells has been demonstrated to have an important role in regulating the synaptic activity. Abnormal mitochondrial dynamics and distribution have been observed in neurodegenerative disorders like Alzheimer, Parkinson, Huntington and Familial Amyotrophic Lateral Sclerosis (FALS) ([@bb0890; @bb0200; @bb0210; @bb1035; @bb0710]). This becomes crucial in the context of OPA1-related DOA, where RGCs are primed to apoptotic cell death, which leads to optic nerve degeneration ([@bb0265]).

DOA fibroblasts cultured in glucose medium may present a mitochondrial network ranging from normal to highly fragmented depending on the OPA1 mutation ([@bb0315; @bb0835]). Balloon-like structures and inhibition of mitochondrial fusion were observed in fibroblasts carrying OPA1 nonsense mutations cultured in galactose medium ([@bb1285]). Mitochondrial structural alterations have been frequently reported in myotubes ([@bb1075]) and skeletal muscle from DOA patients ([@bb0020]), as well as in OPA1 mouse models ([@bb0005; @bb0370]). One specific OPA1 mutation showed altered fusion activity without affecting bioenergetics or increasing sensitivity to apoptosis, suggesting that defective pro-fusion activity is the only pathogenic aspect ([@bb1075]).

Visual loss is also a feature of CMT2A neuropathy, emphasizing the link between optic neuropathies and dysfunction of mitochondrial dynamics ([@bb0265]). However, studies on MFN2-mutant CMT2A fibroblasts failed to show defective mitochondrial fusion, even if a bioenergetic defect was observed ([@bb0700; @bb0025]). Complementation by the fellow MFN1 protein possibly rescued the phenotype in these cells, as demonstrated in single and double mitofusin knockout mouse embryonic fibroblasts (MEFs) ([@bb0385]). Thus, we can speculate that in CMT2A patients, RGCs might be more sensitive to MFN2 dysfunction and suffer abnormal mitochondrial fusion, due to low MFN1 expression levels.

A dominant negative heterozygous *DNM1L* mutation, recently found in a patient affected by severe infantile encephalopathy and optic atrophy, showed a highly filamentous interconnected mitochondrial network in the patient-derived fibroblasts ([@bb1210]). This case represents a demonstration that increased mitochondrial fusion activity may also have dramatic effects, suggesting that the imbalance of mitochondrial fusion--fission plays a central role in the pathogenesis of mitochondrial optic neuropathies.

Finally, a peculiar form of DOA with cataract has been associated with heterozygous mutations in the OPA3 gene ([@bb0905; @bb1160]), whereas recessive mutations are responsible for Costeff syndrome, a 3-methilglutaconic aciduria with a Behr-like phenotype that includes optic atrophy ([@bb0045; @bb0630]). The function of this mitochondrial protein remains poorly understood, but a putative role in fusion--fission of mitochondria remains a strong possibility ([@bb0930]).

Mitochondrial apoptosis {#s0075}
-----------------------

Apoptosis is a form of programmed cell death essential for homeostasis, which is frequently dysregulated in human pathologies such as cancer, neurodegenerative diseases or viral infections ([@bb0750; @bb1155]). Mitochondria are involved in the so-called intrinsic pathway of apoptosis, executing the release of soluble proteins, including cyt c, from the intermembrane space to switch on the caspase activation in the cytosol. The release of these proteins occurs after the loss of mitochondrial OM integrity (mitochondrial outer membrane permeabilization, MOMP), which, in vertebrates, is regulated by the proapoptotic Bcl-2 family members ([@bb0735]).

Both external and internal stimuli can activate different signaling pathways, transducing the signal to mitochondria by Bcl-2 proteins ([@bb0590]). The mechanism by which the Bcl-2 proteins induce OM permeabilization and release the apoptogenic factors remains unclear. The current hypothesis postulates the opening of one of two different channels: the permeability transition pore (PTP) in the IM and the mitochondrial apoptosis-induced channel (MAC) in the OM ([@bb0440; @bb0620]). Whatever is the mechanism of mitochondrial permeabilization, it implies the release of apoptogenic factors (cyt c, AIF, endonuclease G, Smac/DIABLO and Omi/HtrA2) ([@bb1200]).

The last step in apoptosis is the activation of specific proteases called caspases (cysteine aspartyl-specific proteases) that cleave their substrates at aspartic acid (Asp) residues ([@bb1120; @bb0360]). These intracellular proteases are activated by proteolytic cleavage at conserved Asp residues and induce proteolytic cascades, where they activate themselves and each other, finally cleaving many substrates, promoting degradation of cell cytoskeleton and nuclear envelope, loss of adhesion, mitochondrial, Golgi and endoplasmic reticulum fragmentation and DNA condensation and fragmentation, ultimately leading to cell death ([@bb1110]).

Apoptosis is believed to be the final stage of the neurodegenerative processes affecting RGCs in mitochondrial optic neuropathies. However, direct evidence of this is poor ([@bb0345]). Studies on LHON cybrids, using Fas-induced apoptosis, showed that LHON mutant cells were more prone to undergo apoptotic cell death than control cells ([@bb0365]). Similarly, LHON cybrids grown in galactose medium, which forces oxidative metabolism, displayed massive, apoptotic cell death, whereas control cybrids were still able to grow at a reduced rate ([@bb0455]). Under this paradigm, the apoptotic death in LHON cybrids was demonstrated to be caspase-independent, mediated by AIF and Endo G ([@bb1280]). An increased sensitivity to staurosporine, a pro-apoptotic compound, was also found in fibroblasts from OPA1-mutant DOA patients ([@bb0835]), compatible with OPA1 regulation of cyt c release and apoptosis ([@bb0825; @bb0830]). A further link between OPA1 and apoptosis is suggested by its coimmunoprecipitation with AIF ([@bb1285]). Furthermore, overexpression of the p.G93S/*OPA3* mutant protein in HeLa cells led to spontaneous apoptosis ([@bb0930]), confirming the previous observation of an increased sensitivity to staurosporine in fibroblasts carrying the p.G93S/*OPA3* mutation ([@bb0905]).

Mitochondrial biogenesis {#s0080}
------------------------

Mitochondrial biogenesis is a complex process involving the coordinated expression of both nuclear and mitochondrial genes. Since the protein coding capacity of mtDNA is restricted to the expression of only 13 respiratory subunits, nuclear genes are extensively needed for oxidative phosphorylation, heme biosynthesis, mitochondrial protein import, and mtDNA transcription and replication. Expression of the mitochondrial proteome and control of mitochondrial biogenesis are highly regulated by transcription factors and transcriptional coactivators ([@bb0390; @bb0995]).

The most important transcription factors involved in the mitochondrial--nucleus communication are the nuclear respiratory factors 1 and 2 (NRF-1, NRF-2) and the estrogen-related receptor (ERRα), whose expression is driven by the transcriptional coactivators belonging to the peroxisome proliferator-activated receptor γ-coactivator 1 (PGC-1) family ([@bb0990]).

The PGC-1 family is composed of three members (PGC-1α, PGC-1β, PRC), which share a sequence homology and regulate several metabolic pathways such as cellular respiration, thermogenesis and hepatic glucose metabolism ([@bb0995; @bb0605]). Although all these factors can stimulate mitochondrial biogenesis, PGC-1α is mainly involved in the regulation of gluconeogenesis and PGC-1β in the regulation of β-oxidation of fatty acids, and PRC in the coordination of nuclear and mtDNA replication during the cell cycle progression ([@bb0675; @bb0680; @bb0390]).

PGC-1α exhibits a tissue-enriched expression pattern and is highly inducible. This coactivator is enriched in tissues with a high-capacity mitochondrial system, such as brown fat, heart, and oxidative skeletal muscle fibers. PGC-1α is rapidly induced by cold exposure, short-term exercise and fasting, all conditions known to increase ATP and heat demand, and also by nitric oxide ([@bb1005]).

PRC (PGC-1-related coactivator) has several domains homologous to PGC-1α and functional studies indicated that it is able to regulate mitochondrial function in a manner similar to PGC-1α. PRC interacts directly with NRF-1, promoting its activation, and can also activate the transcription of cyt c, a NRF-1 target, through the cooperation with other factors including CREB ([@bb1005]).

The third member of the family, PGC-1β, shows a greater degree of homology to PGC-1α than PRC. The expression pattern of PGC-1β is very similar to that of PGC-1α, being enriched in heart and brown adipose tissue. This coactivator is induced by fasting, but not in response to cold exposure and is able to coordinate mitochondrial biogenesis inducing NRF-1 target genes ([@bb0670]).

NRF-1, NRF-2, ERRα are transcription factors that directly recognize specific sequences in the promoter of several nuclear encoded mitochondrial genes ([@bb0310; @bb0420; @bb1025]). NRF-1 and NRF-2 may coordinate respiratory subunit expression by activating the mitochondrial transcription machinery, since they have been associated with the expression of many nuclear genes that encode subunits of the five OXPHOS complexes and mitochondrial transcription factor A (TFAM) and the two isoforms of mitochondrial transcription factor B (TFB2M) ([@bb1000]). ERR-α, instead, has a direct role in activating NRF-1 and NRF-2 ([@bb1005]).

In mitochondrial disorders, respiratory chain impairment is frequently associated with an increase in mitochondrial mass, a common cellular strategy to compensate for the energy defect. Some degree of mitochondrial proliferation in LHON patient\'s skeletal muscles is shown by the increased subsarcolemmal succinate dehydrogenase (SDH) activity ([@bb0225; @bb1140; @bb0285]). Moreover, an increased succinate-cytochrome c reductase activity, with normal complex III activity, has been reported in blood cells from LHON patients carrying the 11778/*MT-ND4* mutation, suggesting again a nuclear compensatory effect ([@bb1260]). Increased mtDNA copy number has also been reported in blood cells from LHON affected individuals and asymptomatic mutation carriers harboring the 11778/*MT-ND4* and 14484/*MT-ND6* mutations ([@bb1265; @bb0805]). Finally, it has been recently demonstrated that an increase in mitochondrial biogenesis induced by β-estradiol is able to rescue the energetic defect in LHON cybrids ([@bb0465]), supporting the relevance of an efficient mitochondrial biogenesis in LHON and providing a plausible explanation for male prevalence.

Recently, [@bb0780] demonstrated that cells harboring a mutation in the mitochondrial tRNA(Ile) activate mitochondrial biogenesis as a compensatory response triggered by the increase in mitochondrial ROS production. The authors proposed that both the pathogenic mechanism consisting in the abnormal folding of the tRNA(Ile) combined with the existence of a compensatory mechanism can explain the penetrance pattern of this mutation ([@bb0780]). Thus, induction of mitochondrial biogenesis as a compensatory mechanism, which can be triggered by an increased ROS production, may also be important in LHON.

Therapy {#s0085}
=======

LHON and DOA, as well as most of the neurodegenerative syndromes with optic atrophy are considered untreatable conditions; neither supportive therapies with supplements (vitamins, coenzyme Q, etc), nor corticosteroids have been proven to be effective ([@bb0955]). Recent antioxidant molecules, such as idebenone and EPI-743, have been tested with some promising results ([@bb0635; @bb0270; @bb0960]). Genetic approaches to correct the inherited defect have also been proposed and debated ([@bb0500; @bb0815; @bb0860]).

Pharmacological approach {#s0090}
------------------------

The most promising recent results concern two molecules with antioxidant properties, which are believed to by-pass complex I by transferring electrons directly to complex III. The first is idebenone, a quinone analog of coenzyme Q ([@bb0450]), which has been initially reported as possibly effective more than a decade ago, in a LHON case of Japanese ancestry who recovered visual acuity after treatment ([@bb0740]). A few anecdotal reports followed with sometimes contrasting results and the mechanism of action of idebenone remained poorly understood ([@bb0225; @bb0745; @bb0105]). In 2011, the results of the first controlled clinical trial with idebenone ([@bb0635]) were reported, side by side with a retrospective systematic evaluation of a large series of LHON treated patients compared with a similar cohort of matched untreated LHON cases ([@bb0270]). Both studies reached similar results documenting the partial effectiveness of idebenone in ameliorating the final outcome in LHON patients, mostly by increasing the rate of visual recovery after the acute phase ([@bb0800; @bb0935]). Recent studies on the mechanism of action revealed some details on how idebenone works in the cell, and in particular within mitochondria ([@bb0505; @bb0040; @bb0470]). These studies suggest that to be effective and most importantly not toxic, idebenone should be maintained in the reduced state ([@bb0470]), a task that in some cell types appears to be carried out by NAD (P) H:quinone oxidoreductase 1 (NQO1) ([@bb0505]). In the reduced state idebenone provides electron transfer to complex III, which may allow reoxidation of NADH in complex I deficiencies.

A second molecule is α-Tocotrienol quinone, also coded as EPI-743, whose activity depends upon reversible 2e-redox-cycling, and exerts a potent anti-oxidant effect *in vitro* ([@bb1040]). In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in all but 1 of 5 consecutively treated patients with LHON, thus showing promising results that need to be consolidated by a prospective randomized clinical trial ([@bb0960]).

Much attention and investment is currently oriented on the activation of mitochondrial biogenesis as a partially effective compensatory strategy ([@bb1215; @bb1170]). This may be sufficient for some mitochondrial disorders including the inherited optic neuropathies. Molecules that are being experimented in vitro and in animal models include some old drugs, such as bezafibrate and rosiglitazone, and others, which are not currently approved drugs, such as resveratrol and AICAR (5-aminoimidazole-4-carboxamide ribonucleoside). Similarly, we recently showed that estrogens ameliorate the biochemical cellular defects of LHON cybrids, again by activating mitochondrial biogenesis, thus suggesting the potential therapeutic use of estrogen-like molecules ([@bb0465]). Clinical trials in human patients are warranted to understand if this will be a successful therapeutic strategy.

Gene therapy approach {#s0095}
---------------------

The proposal of gene-therapy for mitochondrial diseases, including LHON for which the tissue affected is easily accessible, is mainly based on the approach of nuclear allotopic expression of a recoded and adequately engineered mtDNA gene ([@bb0480; @bb9020; @bb0500]). In the case of LHON, to express a wild-type version of the specific mtDNA-encoded ND subunit in the nucleus, first it needs to be recoded according to the genetic code of nuclear DNA. The recoded wild-type ND subunit is engineered to carry the mitochondrial import signal and is delivered by an adeno-associated virus (AAV) vector to the nucleus of RGCs. Thus, the now nuclear-encoded wild-type ND subunit, after being expressed in the cytoplasm, is targeted to the mitochondria where it is assumed to co-assemble in complex I, competing with the mitochondrial-encoded mutant ND subunit, possibly complementing the biochemical defect. Over the years, serious critiques have been presented on the efficiency and feasibility of this approach ([@bb0815; @bb0860]). However, successful results have been recently reported in an animal model of LHON treated by the allotopic gene-therapy approach, and there are plans to run clinical trials on LHON patients by this gene-therapy strategy ([@bb0415; @bb0655]).

Different approaches of gene therapy have been also presented. Experiments in an animal model of LHON were based on the xenotopic expression of an alternative oxidase (*Saccharomyces cerevisiae* single subunit NADH oxidase Ndi1), which can re-establish the electron flow without coupled proton translocation, thus missing the energy‐conserving function of complex I ([@bb0725; @bb0305]). Another approach was based on the activation of mitochondrial biogenesis by treating cultured cells with donor mtDNA complexed with recombinant human TFAM, which are taken up by cells and driven into mitochondria, ultimately improving their respiration ([@bb0575]).

Finally, gene therapy for OPA1-related DOA patients is a feasible hypothesis, even if, at present there are a dearth of reports on this issue. However, contrary to mtDNA-based diseases, the techniques for gene replacement therapy are well developed for nuclear gene defects, and the recent successful trial with and AAV-mediated gene replacement for Leber congenital amaurosis provides a good example, which may be hopefully applied soon to DOA patients as well ([@bb0715]).

Future directions and conclusions {#s0100}
=================================

Many complexities of mitochondrial optic neuropathies still remain poorly understood, mainly due to the lack of a true genetic animal model for mtDNA-based optic neuropathies, such as LHON. A number of animal models were created with the specific purpose of reproducing a mitochondrial optic neuropathy by biochemical manipulations ([@bb1300]), or by ingenious engineering of gene expression ([@bb0880; @bb0415; @bb0725]). However, none of these models faithfully fulfills the real situation of LHON, a disease with homoplasmic mutant mtDNA that hits with incomplete penetrance only the RGC system, ultimately leading to optic atrophy. A few true mito-mouse models with mtDNA mutations exist, but unfortunately the eye and, in particular, the RGC system and optic nerve have not been properly investigated ([@bb1195; @bb0795]). Thus, the most important challenge for the future will be to firmly establish an animal model of LHON, with which to work out many of the unsolved questions and accelerate effective therapies.

Two different animal models for OPA1-related DOA currently exist, and are being investigated ([@bb1230]). Both animal models reproduced, with slightly different features, an age-dependent optic nerve dysfunction mimicking the slowly progressive pathology affecting human optic nerves in DOA patients with OPA1 mutations. Currently, the most provocative observation, which highlights the usefulness of animal models, concerns the precocious involvement of RGC dendrites, with dendritic pruning, retraction of mitochondria towards the soma, and mitochondrial fragmentation, preceding dendritic loss in animals already showing visual dysfunction ([@bb1225; @bb1235]). Thus, at a time-point for which there is still complete integrity of RGCs somata and axons, the first sign of pathology may be in the afferent synaptic connectivity of these cells, observed in the presence of abnormal mitochondrial distribution and fusion--fission balance.

In conclusion, the eye, and specifically the optic nerve, is an ideal system with which to observe and perhaps treat the consequences of mitochondrial form of neurodegeneration. The eye\'s particular vulnerability to mitochondrial diseases and its remarkable access should be exploited. Thus, the eye is a true "mito-window" on the brain.
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###### 

Pathogenic mtDNA mutations associated with Leber hereditary optic neuropathy, all reported by [@bb0770], except a reported by [@bb1290] and b by [@bb1315].

                                                Mutation       Gene     Change
  --------------------------------------------- -------------- -------- --------
  Common variants (\~ 90%)                      11778 G \> A   MT-ND4   R340H
  3460 G \> A                                   MT-ND1         A52T     
  14484 T \> C                                  MT-ND6         M64V     
  Rare variants (\~ 10%)                        3635 G \> A    MT-ND1   S110N
  3733 G \> A                                   E143H                   
  4171 C \> A                                   L289M                   
  4640 C \> A                                   MT-ND2         I57M     
  5244 G \> A                                   G259S                   
  10663 T \> C                                  MT-ND4L        V65A     
  10680 G \> A^a^                               A71T                    
  14482 C \> A, C \> G                          MT-ND6         M64I     
  14495 A \> G                                  L60S                    
  14502 T \> C^b^                               I58V                    
  14568 C \> T                                  G36S                    
  Reported rare variants in ND subunits         3700 G \> A    MT-ND1   A112T
  3736 G \> A                                   V144I                   
  4025 T \> C                                   T240M                   
  4160 T \> C                                   L285P                   
  4640 C \> A                                   MT-ND2         I57M     
  4852 T \> A                                   L128Q                   
  5244 G \> A                                   G259S                   
  10237 T \> C                                  MT-ND3         I60T     
  10543 A \> G                                  MT-ND4L        H25R     
  10591 T \> G                                  F41C                    
  11253 T \> C                                  MT-ND4         I165T    
  11696 G \> A                                  V312I                   
  11874 C \> A                                  T372N                   
  12782 T \> G                                  MT-ND5         I149S    
  12811 T \> C                                  Y159H                   
  12848 C \> T                                  A171V                   
  13051 G \> A                                  G239S                   
  13379 A \> C                                  H348P                   
  13637 A \> G                                  Q434R                   
  13730 G \> A                                  G465E                   
  14279 G \> A                                  MT-ND6         S132L    
  14325 T \> C                                  N117D                   
  14498 C \> T                                  Y59C                    
  14596 A \> T                                  I26M                    
  Reported rare variants in other mtDNA genes   7623 C \> T    MT-CO2   T13I
  8668 T \> C                                   MT-ATP6        W48R     
  8836 A \> G                                   M104V                   
  9016 A \> G                                   I164V                   
  9101 T \> C                                   I192T                   
  9660 A \> C                                   MT-CO3         M152L    
  9738 G \> T                                   A178S                   
  9804 G \> A                                   A200T                   
  14831 G \> A                                  MT-CYB         A29T     
  15674 T \> C                                  S310P                   

###### 

Pathogenic mtDNA mutations associated with overlapping phenotypes.

  Mutation       Gene               Clinical phenotype   Reference
  -------------- ------------------ -------------------- -----------
  3376 G \> A    MT-ND1             LHON/MELAS           [@bb0140]
  3697 G \> A    LHON/MELAS         [@bb1080]            
  10197 G \> A   MT-ND3             LHON/dystonia        [@bb1205]
  13042 G \> A   MT-ND5             LHON/MELAS/MERFF     [@bb1145]
  13045 A \> C   MELAS/LHON/Leigh   [@bb0685]            
  13513 G \> A   LHON/MELAS/Leigh   [@bb0155]            
  13514 G \> A   LHON/MELAS         [@bb0355]            
  14459 G \> A   MT-ND6             LHON/dystonia        [@bb0595]
  14600 G \> A   LHON/MELAS/Leigh   [@bb0720]            

###### 

List of optic atrophy loci (OPA) associated with optic atrophy (OA).

  Gene/locus   Protein     Location         Heritance   Phenotype             OMIM                 Reference
  ------------ ----------- ---------------- ----------- --------------------- -------------------- ----------------------
  OPA1         OPA1        3q29             Dominant    OA                    \#[165500](165500)   [@bb0015]; [@bb0380]
  OPA2         --          Xp11.4--p11.21   X-linked    OA with early onset   \#[311050](311050)   [@bb0060]
  OPA3         OPA3        19q13.32         Dominant    OA with cataract      \#[165300](165300)   [@bb0905]
  OPA4         --          18q12.2--q12.3   Dominant    OA                    \#[605293](605293)   [@bb0610]
  OPA5         --          22q12.1--q13.1   Dominant    OA                    \#[610708](610708)   [@bb9000]
  OPA6         --          8q21--q22        Dominant    OA                    \#[258500](258500)   [@bb9005]
  OPA7/ROA1    TMEM126A    11q14.1          Recessive   OA                    \#[612989](612989)   [@bb0520]
  OPA8         --          16q21--q22       Dominant    OA with deafness      --                   [@bb0275]
  WFS1         Wolframin   4p16.1           Dominant    OA with deafness      --                   [@bb0900]

###### 

List of major genes associated with optic atrophy syndromes and encoding for proteins with a putative or demonstrated mitochondrial function.

  Gene     Protein       Location   Heritance   Phenotype                                 OMIM                 Reference
  -------- ------------- ---------- ----------- ----------------------------------------- -------------------- -----------
  OPA1     OPA1          3q29       Dominant    OPA1 plus                                 \#[125250](125250)   [@bb0020]
  OPA3     OPA3          19q13.32   Recessive   Costeff syndrome                          \#[258501](258501)   [@bb0045]
  FXN      Frataxin      9q21.11    Recessive   Fredreich ataxia                          \#[229300](229300)   [@bb0425]
  TIMM8A   TIMM8A        Xq22       X-linked    Mohr--Tranebjærg syndrome                 \#[304700](304700)   [@bb1135]
  SPG7     Paraplegin    16q24.3    Recessive   Spastic paraplegia-7                      \#[607259](607259)   [@bb0295]
  MFN2     Mitofusin 2   1p36.22    Dominant    Charcot--Marie--Tooth disease, type 2A2   \#[609260](609260)   [@bb1330]
  DNM1L    DNM1L         12p11.21   Dominant    Encephalopathy                            \#[614388](614388)   [@bb1210]
  WFS1     Wolframin     4p16.1     Recessive   Wolfram syndrome 1                        \#[222300](222300)   [@bb1095]
  CISD2    CISD2         4q24       Recessive   Wolfram syndrome 2                        \#[604928](604928)   [@bb0030]
  SDHA     Complex II    5p15       Dominant    Late-onset optic atrophy and ataxia       --                   [@bb0135]
